-$0.33 expected earnings per share for scPharmaceuticals Inc. (NASDAQ:SCPH) this quarter
Equity research analysts expect scPharmaceuticals Inc. (NASDAQ:SCPH – Get Rating) to report earnings per share (EPS) of ($0.33) for the current fiscal quarter, reports Zacks Investment Research. No analyst has made earnings estimates for scPharmaceuticals. The highest EPS estimate is ($0.29) and the lowest is ($0.36). scPharmaceuticals reported earnings of ($0.26) per share in the same quarter last year, which would indicate a negative 26.9% year-over-year growth rate. The company is due to release its next results on Monday, January 1.
According to Zacks, analysts expect scPharmaceuticals to report annual earnings of ($1.51) per share for the current fiscal year, with EPS estimates ranging from ($1.62) to ($1.37). $). For next year, analysts expect the company to post earnings of ($1.15) per share, with EPS estimates ranging from ($1.50) to ($0.73). Zacks earnings per share averages are an average average based on a survey of sell-side research analysts who provide coverage for scPharmaceuticals.
scPharmaceuticals (NASDAQ:SCPH – Get Rating) last reported quarterly earnings data on Monday, May 16. The company reported ($0.28) earnings per share for the quarter, beating analyst consensus estimates of ($0.36) by $0.08.
Several analysts have recently commented on SCPH stock. SVB Leerink raised its price target on scPharmaceuticals shares to $6.00 and gave the company a “market performance” rating in a Tuesday, May 17 research report. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on scPharmaceuticals shares in a research note on Tuesday, April 12.
scPharmaceuticals stock traded down $0.05 at midday Wednesday, hitting $4.83. 10,803 shares of the company were traded, against an average volume of 33,201. The company has a debt ratio of 0.10, a current ratio of 4.81 and a quick ratio of 4.81. scPharmaceuticals has a 12-month low of $3.48 and a 12-month high of $7.28. The company has a market capitalization of $132.20 million, a price-earnings ratio of -4.60 and a beta of 0.43. The company has a 50-day moving average of $5.06 and a 200-day moving average of $4.92.
Separately, major shareholder 5Am Partners Iv, Llc sold 270,000 shares of the company in a transaction on Monday, April 11. The shares were sold at an average price of $5.00, for a total value of $1,350,000.00. Following the completion of the transaction, the insider now directly owns 120,966 shares of the company, valued at approximately $604,830. The transaction was disclosed in a document filed with the SEC, which can be accessed on the SEC’s website. 3.71% of the shares are held by company insiders.
Several hedge funds and other institutional investors have recently changed their holdings in the company. Advisor Group Holdings Inc. increased its holdings of scPharmaceuticals shares by 980.4% in the third quarter. Advisor Group Holdings Inc. now owns 3,857 shares of the company valued at $25,000 after purchasing an additional 3,500 shares during the period. Sandy Cove Advisors LLC acquired a new stake in scPharmaceuticals during the fourth quarter worth approximately $53,000. Envestnet Asset Management Inc. increased its holdings in scPharmaceuticals by 20.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 12,882 shares of the company worth $65,000 after buying 2,186 additional shares in the last quarter. IPG Investment Advisors LLC acquired a new stake in scPharmaceuticals during the fourth quarter worth approximately $72,000. Finally, Thomasville National Bank acquired a new stake in scPharmaceuticals during the fourth quarter worth approximately $75,000. Institutional investors and hedge funds own 72.84% of the company’s shares.
scPharmaceuticals Company Profile (Get an evaluation)
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The Company’s lead product candidate is FUROSCIX which consists of a formulation of furosemide, which is delivered through an infuser to the body for the treatment of congestion in patients with heart failure.
Get a Free Copy of Zacks Research Report on scPharmaceuticals (SCPH)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for scPharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for scPharmaceuticals and related companies with MarketBeat.com’s free daily email newsletter.